NCT05679921 2025-07-16
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
Yonsei University
Phase 2 Recruiting
Clinical Trials
16 trialsNCT02207309 2024-08-09
Pazopanib Maintenance Phase II
Ludwig-Maximilians - University of Munich
Phase 2 Terminated
NCT03798106 2023-06-12
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
Yonsei University
Phase 2 Completed
NCT01462630 2022-08-19
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Fox Chase Cancer Center
Phase 2 Completed
NCT02357810 2022-06-07
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Northwestern University
Phase 2 Completed
NCT01532687 2021-09-27
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01543802 2021-01-26
NOPASS
Heidelberg University
Phase 2 Terminated
NCT01956669 2020-08-12
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Novartis
Phase 2 Completed
NCT02300545 2020-08-05
Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Washington University School of Medicine
Phase 2 Completed
NCT01593748 2020-04-06
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Medical University of South Carolina
Phase 2 Completed
NCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT02575066 2019-06-27
PASART-2
The Netherlands Cancer Institute
Phase 2 Terminated
NCT03149120 2017-08-22
Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
NYU Langone Health
Phase 2 Withdrawn
NCT01861951 2017-08-21
EPAZ
Hannover Medical School
Phase 2 Completed
NCT02367651 2016-10-12
Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma
GlaxoSmithKline
Phase 2 Withdrawn
NCT00297258 2016-02-03
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
GlaxoSmithKline
Phase 2 Completed